Brinckerhoff Quoted on Myriad Ruling

31 July 2011 Pharmacogenomics Reporter News

Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in Pharmacogenomics Reporter on July 31, 2011 titled "Appeals Court Decides Isolated DNA Patentable, Myriad's Analytical Method Claims Not." Brinckerhoff discusses the Court of Appeals for the Federal Circuit’s ruling that isolated gene sequences are patentable, stating that the decision could have a far-reaching impact on other patents and personalized medicine type claims. She adds that practitioners and patent holders may want to review pending and granted claims to determine if they are affected by recent decisions regarding gene patent eligibility.

Related Services

Insights

DOL Rolls Back Trump Administration’s Independent Contractor Rule
05 May 2021
Labor & Employment Law Perspectives
190 Across the Finish Line: CFTC Adopts New Bankruptcy Rules for FCMS and DCOS
05 May 2021
The Journal on the Law of Investment & Risk Management Products, Futures & Derivatives Law Report
Understanding SPACs' Hidden Capital Costs
05 May 2021
Law360
The Export Import Bank of the United States: Priorities and Programs Supporting U.S. Businesses and Jobs
04 May 2021
Manufacturing Industry Advisor
Home Care 100
27-30 June 2021
Marco Island, FL
2021 AANP National Conference
15 June - 31 August 2021
Virtual Conference
HCCA Orange County Regional Healthcare Compliance Conference
11 June 2021
Virtual Conference
Rx Pricing and Reimbursement Summit
24-25 May 2021
Virtual Conference